Everolimus in patients with autosomal dominant polycystic kidney disease

New England Journal of Medicine

Volumn 363, Issue 9, 2010, Pages 830-840

  Walz, Gerd ^a   Budde, Klemens ^b   Mannaa, Marwan ^c   Nürnberger, Jens ^d   Wanner, Christoph ^e   Sommerer, Claudia ^f   Kunzendorf, Ulrich ^g   Banas, Bernhard ^h   Hörl, Walter H ⁿ   Obermüller, Nicholas ⁱ   Arns, Wolfgang ^j   Pavenstädt, Hermann ^k   Gaedeke, Jens ^b   Büchert, Martin ^a   May, Christoph ^l   Gschaidmeier, Harald ^l   Kramer, Stefan ^l   Eckardt, Kai Uwe ^m  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Campus Virchow ^*  (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j Merheim Medical Center   (Germany)

^k UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^l Novartis Germany   (Germany)

^m UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PLACEBO;

ABDOMINAL PAIN; ACNE; ADULT; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BACTERIAL GENE; BENIGN TUMOR; BODY SURFACE; BODY WEIGHT; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; EPISTAXIS; FEMALE; FLANK PAIN; FOLLICULITIS; GASTRITIS; GLOMERULUS FILTRATION RATE; GROWTH; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFECTION RATE; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAMMAL; MOUTH ULCER; MULTICENTER STUDY; MYALGIA; MYOSITIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CYST; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; STOMATITIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; URINARY TRACT INFECTION; VOMITING;

EID: 77956035166     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1003491     Document Type: Article

References (20)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-301. (Pubitemid 46552051)
2. Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359:1477-85.
3. Wilson PD. Polycystic kidney disease. N Engl J Med 2004;350:151-64.
4. Singla V, Reiter JF. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science 2006;313:629-33.
5. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51.
6. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006;103:5466-71.
7. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006;21:598-604. (Pubitemid 43372904)
8. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007;30:253-9.
9. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008;19:631-8.
10. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54. [Erratum, Ann Intern Med 2008;149:519.]
11. Troendle JF, Liu A, Wu C, Yu KF. Sequential testing for efficacy in clinical trials with non-transient effects. Stat Med 2005;24:3239-50. (Pubitemid 41548978)
12. King BF, Torres VE, Brummer ME, et al. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:2214-21.
13. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003;64:1035-45.
14. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006;354:2122-30.
15. Molenberghs G, Kenward MG. Missing data in clinical studies. Chichester, United Kingdom: John Wiley, 2007.
16. Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010;21:1031-40.
17. Hartman TR, Liu D, Zilfou JT, et al. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 2009;18:151-63.
18. Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, Cheadle JP. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 2009;18:2166-76.
19. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20:2493-502.
20. Wong H, Vivian L, Weiler G, Filler G. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 2004;43:624-8.